Transcatheter Market

• Rising spread of aortic valve stenosis is driving the market growth

Market CAGR for transcatheter is being driven by the rising population of elderly people and growing demand for minimal-invasive processes. Transcatheter aortic valve replacement is a minimally invasive technique that is in high demand due to the increased prevalence of aortic valve stenosis (AS), the growing percentage of elderly population, and the rising need for minimally invasive procedures in general. In the United States, 92,000 TAVR valves were implanted in patients in 2021, according to Cardiovascular Business magazine. The pandemic had a prominent impact on the world's economy and healthcare system.

Major producers of cardiovascular equipment experienced significant revenue losses since the pandemic reduced the number of medical operations overall and affected the supply chain for medical devices.

For instance, Boston Scientific's quarterly sales showed a 12% loss in the cardiovascular device market in 2020, while Medtronic's 2020 quarterly financial reports showed a decrease of 33% in its cardiac and vascular portfolio. As a result, the fall in segmental income for important participants points to a serious setback that hurt the sector. Additionally, adults with congenital heart disease were possibly at high risk for mortality and other problems during the pandemic, according to an article titled "COVID-19 in Adults with Congenital Heart Disease" that was published in the Journal of the American College of Cardiology in April 2021.

Additionally, industry innovation keeps improving prospects. For instance, in September 2021, the U.S. FDA approved Abbott Laboratories, Inc.'s Epic Plus, and Epic Plus Supra Stented Tissue Valves to improve the range of treatment options for patients with AS illness. Due to technological advancements in TAVR operations, the market is growing. Additionally, important manufacturers take on several strategic projects that support the development of the sector.

The elderly (65 years of age or older) are more prone to AS. For instance, according to the study Epidemiology of AS and aortic incompetence (AI), AS/AI prevalence was comparable over the world in February 2020. Between rich and developing nations, there are major differences in the epidemiology of AS. In addition, the prevalence of AS rises sharply with age, reaching 9.8% in people 80 to 89 years old, 3.9% in people 70 to 79 years old, 1.3% in people 60 to 69 years old, and 0.2% in people 50 to 59 years old.

As a result, these studies show that patients with AS use transcatheter heart valves, and the demand for TAVR is anticipated to increase throughout the projected period. Thus, driving the Transcatheter market revenue.

The Global Transcatheter Market Industry is poised for remarkable growth, with projections indicating a rise from 2.69 USD Billion in 2024 to 14.6 USD Billion by 2035. This trajectory suggests a compound annual growth rate of 16.64% from 2025 to 2035, reflecting the increasing demand for transcatheter solutions driven by various factors. These include the rising prevalence of cardiovascular diseases, technological advancements, and a growing preference for minimally invasive procedures. The market's expansion is likely to be supported by ongoing innovations and a favorable regulatory environment, positioning transcatheter technologies as a cornerstone of modern cardiovascular care.

A favorable regulatory landscape is essential for the growth of the Global Transcatheter Market Industry. Regulatory bodies are increasingly recognizing the benefits of transcatheter technologies, expediting the approval processes for new devices. This supportive environment encourages innovation and investment in research and development, leading to the introduction of novel transcatheter solutions. For instance, recent approvals for advanced transcatheter heart valves have facilitated their widespread adoption, contributing to market growth. As regulatory frameworks continue to evolve, they are likely to foster a conducive atmosphere for the expansion of the transcatheter market.

Enhanced awareness and education regarding transcatheter procedures among healthcare professionals and patients are pivotal for the Global Transcatheter Market Industry. Educational initiatives aimed at informing stakeholders about the benefits and advancements in transcatheter technologies have led to increased acceptance and utilization. As more healthcare providers become proficient in these techniques, the market is expected to experience substantial growth. This trend is further supported by collaborative efforts between medical associations and educational institutions to disseminate knowledge, ultimately driving the adoption of transcatheter interventions across various demographics.

The increasing incidence of cardiovascular diseases globally is a primary driver for the Global Transcatheter Market Industry. As populations age and lifestyle-related health issues become more prevalent, the demand for minimally invasive procedures rises. For instance, cardiovascular diseases are projected to affect millions worldwide, leading to a surge in transcatheter interventions. The market is expected to reach 2.69 USD Billion in 2024, reflecting the urgent need for innovative solutions. This trend indicates a growing reliance on transcatheter technologies, which offer reduced recovery times and lower complication rates compared to traditional surgical methods.

Technological innovations play a crucial role in shaping the Global Transcatheter Market Industry. The development of advanced transcatheter heart valves and other devices enhances procedural success rates and patient outcomes. For example, the introduction of next-generation devices equipped with improved delivery systems and biocompatible materials has revolutionized treatment options. These advancements not only improve efficacy but also expand the range of patients eligible for transcatheter procedures. As a result, the market is anticipated to grow significantly, with projections indicating a rise to 14.6 USD Billion by 2035, driven by continuous innovation and enhanced clinical performance.

The growing preference for minimally invasive procedures among both patients and healthcare providers is a significant driver for the Global Transcatheter Market Industry. Patients often seek options that minimize recovery time and hospital stays, leading to a shift away from traditional surgical methods. Healthcare providers are increasingly adopting transcatheter techniques due to their ability to reduce complications and improve patient satisfaction. This trend is reflected in the projected compound annual growth rate of 16.64% from 2025 to 2035, indicating a robust expansion of the market as more healthcare facilities integrate these procedures into their offerings.

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Transcatheter market area will dominate this market. Due to its well-established healthcare system and the rising prevalence of conditions like regurgitation and AS. Growth in the region is projected to be fueled by the increased prevalence of AS illnesses and aortic regurgitation in the populace over the anticipated period.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Europe’s Transcatheter market accounts for the second-largest market share. The market is influenced by several variables, including an increase in TAVR treatments, economic growth, regulatory repercussions, and new product introductions in the EU. Further, the German Transcatheter market held the largest market share, and the UK Transcatheter market was the fastest-growing market in the European region

The Asia-Pacific Transcatheter Market is anticipated to expand at the quickest CAGR. Due to rising aortic stenosis disease prevalence, expanding healthcare infrastructure, and increased knowledge of transcatheter aortic valve implantation. As a result of its huge population and several cardiovascular and lifestyle disorders, Asia-Pacific presents lucrative potential for participants in the transcatheter aortic valve implantation market. Moreover, China’s Transcatheter market held the largest market share, and the Indian Transcatheter market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing largely across research & development activities to expand their product lines, which will help the Transcatheter market, grow substantially. Market leaders are also undertaking a variety of strategies to extend their presence, with vital market developments including new product developments, contracts & agreements, mergers & acquisitions, investments, and collaboration with other similar organizations. To grow and sustain in a more competitive and rising market climate, the Transcatheter industry must offer cost-effective items.

Manufacturing locally to reduce operational expenses is one of the key business tactics used by manufacturers in the Transcatheter industry to benefit clients and increase the market sector. In recent years, the Transcatheter industry has offered some of the most significant advantages to medicine. Major players in the Transcatheter market, including Edwards Lifesciences Corporation, Meril Life Sciences Pvt. Ltd., Braile Biomedica, Venus Medtech, Boston Scientific Corporation, JenaValve Technology Inc., Abbot Laboratories, Medtronic PLc, Bracco Diagnostics Inc., Cook Medical Inc., and others, are trying to extend market demand by investing in research and development operations.

The development, production, and marketing of devices for structural heart disease, critical care, and postoperative monitoring are the main business activities of Edwards Lifesciences Corp (Edwards Lifesciences). The company produces pressure monitoring equipment, transcatheter cardiac valves, hemodynamic monitoring equipment, surgical valve replacement equipment, and related tools and accessories. 

Its products are used in several therapeutic procedures, including transcatheter aortic valve replacement (TAVR), blood preservation, infection control, accelerated surgical recovery, and the treatment of clotting, hypotension, and sepsis. Among other places, the company markets its goods through a network of independent distributors in North America, Europe, and Asia-Pacific. In November 2022, The EVOQUE transcatheter tricuspid valve replacement device from Edwards Lifesciences Corporation produced positive results after one year for patients treated in the single-arm, prospective, worldwide, multi-center TRISCEND research, which looked at safety, effectiveness, and quality of life.

The information was provided at PCR London Valves 2022's late-breaking trials session.

A wide variety of healthcare goods are discovered, developed, produced, and sold by Abbott Laboratories (Abbott), including branded generic medications, diagnostic tools and procedures, and infant, child, & nutritional supplements for adults. The company also provides various medical devices, like those for neuromodulation, electrophysiology, rhythm control, vascular and structural cardiac devices, and heart failure. 

The business also sells dietary supplements, minerals, and nutrition goods. It runs manufacturing sites all around the world and has research and development centers in the US, China, Colombia, India, Singapore, Spain, and the UK. The corporation sells its goods across Africa, the Middle East, Latin America, North America, and the Asia-Pacific region. In January 2023, To treat patients with severe aortic stenosis who are at peak or extremely high risk for open-heart surgery, Navitor, Abbott's most recent generation transcatheter aortic valve implantation (TAVI) technology, has been given FDA approval.

The company's extensive transcatheter structural heart portfolio, which includes the Navitor TAVI device, offers physicians and patients less invasive treatment alternatives for some of the most prevalent and critical heart ailments.